Findings regarding the association between n-3 polyunsaturated fatty acid (PUFA) status and depression are conflicting. Thus, the authors studied associations between PUFA intake and depressive symptoms. In 1996, depressive symptoms were assessed in a subsample of participants from the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) Study using the Center for Epidemiologic Studies Depression Scale (CES-D). In 2007-2009, information on CES-D score, history of depression, and use of antidepressant medication was obtained. Intakes of n-3 PUFAs were estimated from repeated 24-hour dietary records collected during 1994-1996. Subjects with depressive symptoms (cases) were identified using CES-D scores greater than 15 and/or antidepressant use. Logistic regression analyses were used. Cross-sectional (n ¼ 2,744) and longitudinal (n ¼ 1,235) associations between quartiles of PUFA intake and depressive symptoms were estimated. In cross-sectional analyses, quartile of n-3 PUFA intake was associated with lower odds of depressive symptoms (fourth quartile vs. first: odds ratio ¼ 0.74, 95% confidence interval: 0.58, 0.95; P for trend ¼ 0.001). No association between PUFA intake and incidence of depressive symptoms over 13 years was detected. This study provides new insights into the PUFAdepression link. While no association between n-3 PUFA intake and incidence of depressive symptoms was detected, an association was observed in cross-sectional analyses, which may reflect unhealthy dietary patterns among subjects with depressive symptoms.
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As a result of its high prevalence and substantial adverse impact on functioning, depression is of major concern. In Europe, depression is the third-leading contributor to the total burden of disease, measured in disability-adjusted life years (1) . Estimates suggest that depression will become the second-leading cause of morbidity by 2020 worldwide (2) . Among the elderly, management and prevention of depressive symptoms are especially critical because depression is interrelated with other chronic medical conditions and with age-related cognitive impairment and functional decline (3) . In particular, depressive symptoms could be either a risk factor for or a prodromal sign of cognitive decline preceding the onset of Alzheimer's disease (4-7).
Identification of modifiable behavioral and environmental factors that may help prevent depressive disorder is critical from a public health viewpoint. Dietary factors constitute a promising target, since, in addition to the biologic plausibility of diet's influencing mental health, there is substantial opportunity for improving people's nutritional status. A growing interest has emerged in the potential beneficial effect of n-3 polyunsaturated fatty acids (PUFAs) on depressive symptoms (6) (7) (8) .
In experimental studies, investigators have proposed underlying neurophysiologic mechanisms arguing for a relation between depression and n-3 PUFAs, including the antiinflammatory properties of these nutrients and their potential roles in regulation of serotoninergic and dopaminergic neurotransmitters, gene transcription in the central nervous system, and determination of neural membrane fluidity (8) . Observational and intervention studies reporting associations between n-3 PUFAs and clinical depression or depressive symptoms are plentiful and have been extensively reviewed (9) (10) (11) (12) (13) (14) (15) (16) .
Mostly, randomized clinical trials have been designed to test the efficacy of n-3 PUFA supplementation as adjunctive therapy or monotherapy in the treatment of depression. Despite the large heterogeneity among studies in terms of type, source, and dose of n-3 fatty acids, duration of intervention, and sample size, findings consistently support a favorable effect of PUFA supplementation, particularly eicosapentaenoic acid (EPA), on depressive symptoms (9, (13) (14) (15) (16) . Data from ecologic studies (17, 18) have shown a correlation between fish consumption and the prevalence of depression. In addition, depressed patients have been shown to exhibit lower levels of n-3 PUFAs than controls (11) .
To our knowledge, only 1 randomized clinical trial, carried out in a general population, focused on the relation between EPA and docosahexaenoic acid (DHA) supplementation and subsequent depressive symptoms (19) . The authors did not report any statistically significant associations. Observational studies that have found significant associations between intake or blood level of n-3 PUFAs and depression/ depressive symptoms have been mostly cross-sectional (10, 12) , while longitudinal studies have not supported a protective effect (10, 20) . Thus, there is an apparent inconsistency between cross-sectional and longitudinal studies regarding n-3 PUFAs and depressive symptoms, and to our knowledge no study has undertaken both approaches using the same data set.
Our aim in the present analysis was to investigate crosssectional and longitudinal associations between dietary intake of several types of PUFAs and depressive symptoms among community-dwelling elderly. Effect modification by gender and interactions between PUFAs were tested.
MATERIALS AND METHODS
In the present paper, participants with and without depressive symptoms are referred to cases and noncases, respectively.
Study population
Initially, the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) Study was designed as a randomized double-blind, placebo-controlled trial including 12,741 persons with a planned follow-up period of 8 years (1994-2002) . The aim was to test the efficacy of daily supplementation with antioxidant vitamins and minerals at nutritional doses in lowering the incidence of cancer, ischemic heart disease, and overall mortality (21, 22 
Dietary data
During the SU.VI.MAX Study, subjects were invited to complete a 24-hour dietary record every 2 months, for a total of 6 records per year, so that all days of the week and all seasons were covered to account for individual variability in intake. Data were collected through the Minitel Telematic Network, small terminals widely used in France as an adjunct to telephones. At baseline (1994), subjects received a small central processing unit specifically developed for the study and containing special software that allowed subjects to fill out the computerized dietary record off-line and transmit data during brief telephone connections. Subjects were assisted by an instruction manual for coding food portions which included validated photographs of more than 250 foods represented in several different portion sizes (23) .
Nutrient and alcohol intakes were estimated using a published French food composition table (24) . Intakes of n-3 long-chain PUFAs were calculated as the sum of EPA, DHA, and docosapentaenoic acid (DPA). Total n-3 PUFA intake was calculated as the sum of a-linolenic acid and n-3 long-chain PUFA intake. Total n-6 PUFA intake was calculated as the sum of linoleic acid and arachidonic acid intakes.
Evaluation of depressive symptoms
Depressive symptoms were assessed by means of the validated French version of the Center for Epidemiologic Studies Depression Scale (CES-D) in an ancillary study in 1996 and among subjects participating in SU.VI.MAX 2 in 2007-2009 (25, 26) . The CES-D was self-administered at home. CES-D scores range from 0 to 60, with a lower score corresponding to fewer depressive symptoms. A cutoff of >15 has been proposed to identify persons with depressive symptoms (25) .
Covariates
At baseline (1994), information on gender, date of birth, medication use (including antidepressant medication use), smoking status, physical activity, marital status, and educational level was collected. At the first follow-up clinical examination (1995) (1996) , anthropometric and clinical measurements were obtained. Weight was measured using an electronic scale, with subjects wearing indoor clothing and no shoes. Height was measured under the same conditions with a wall-mounted stadiometer. Blood pressure was measured using a standardized procedure with a mercury sphygmomanometer. It was taken once on each arm in subjects who had been lying down for 10 minutes. The mean of these 2 measurements was used for analyses.
At the SU.VI. MAX 2 (2007 MAX 2 ( -2009 ) clinical examination, global cognitive function was assessed using a French version of the Mini-Mental State Examination (27, 28) . History of depression and date of diagnosis, as well as use of antidepressant medication, were self-reported in the SU.VI.MAX 2 questionnaire.
Since baseline (1994), in cases of suspected cardiovascular disease, relevant medical data (clinical, biochemical, histologic, and radiologic reports) were requested from the participants, physicians, and/or hospitals. All reported cardiovascular events were reviewed and validated by an independent expert committee.
Statistical analysis
For the cross-sectional models, we selected those participants who had completed at least three 24-hour dietary records during the first 2 years of follow-up and had baseline CES-D scores. Subjects with missing values for one or more covariates were excluded. The presence of depressive symptoms was defined as a CES-D score above 15. From that sample of participants, we excluded those with no longitudinal data before fitting the longitudinal models. Cases were defined as a CES-D score greater than 15 or use of antidepressant medication at the time of the SU.VI.MAX 2 clinical examination. Prevalent cases were excluded on the basis of antidepressant medication use in 1994 or a self-reported history of depression before the initial CES-D assessment.
Energy adjustment was performed using the residual method (29) . Quartiles of PUFA intake were determined and used in the models. Body mass index was calculated as the ratio of weight (kg) to squared height (m 2 ). Hypertension at baseline was defined as systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg or reported use of antihypertensive medication.
Cross-sectional and longitudinal associations between depressive symptoms and PUFA intake (as quartiles) were estimated using logistic regression, which provided odds ratios and 95% confidence intervals. Linear trends were estimated by modeling quartiles of PUFA intake treated as an ordinal variable.
Descriptive results regarding the baseline characteristics are reported as mean values (with standard deviations) or percentages across quartiles of n-3 PUFA intake. Reported P values refer to the Kruskal-Wallis test or the v 2 trend test, as appropriate. Participants with and without longitudinal data were compared.
Potentially confounding factors were identified using evidence from the literature (30) (31) (32) (33) . Factors displaying an association with depressive symptoms in explanatory univariate analyses (0.20 significance level) were included in the multivariate model. Supplementation group was forced into the final model. The initial model represents unadjusted analyses. In turn, the cross-sectional multivariate models accounted for gender, age, educational level (primary, secondary, or university education), physical activity (irregular, equivalent of walking <1 hour/day, or equivalent of walking 1 hour/day), energy intake, excluding alcohol (kcal/day), number of 24-hour dietary records, marital status (cohabiting vs. living alone), intervention group (active vs. placebo), body mass index, alcohol consumption (g/day), vegetable and fruit consumption (g/day), and saturated fatty acid intake (g/day). The longitudinal multivariate models accounted for gender, age, educational level (primary, secondary, or university education), energy intake, excluding alcohol (kcal/day), number of 24-hour dietary records, intervention group (active vs. placebo), tobacco use (all types; never, former, or current use), and alcohol consumption (g/day). In the models focusing on n-3 PUFA intake, results were adjusted for total n-6 PUFA intake, and vice versa.
Other covariates, namely baseline hypertension, MiniMental State Examination score at the SU.VI.MAX 2 clinical examination (in the longitudinal analyses only), and history of cardiovascular disease (in the longitudinal analyses only), were tested but not retained because of nonsignificant associations.
In both the cross-sectional and longitudinal analyses, we tested for interactions between supplementation group or gender and PUFA intake, between a-linolenic acid and linoleic acid intakes, and between total n-3 and total n-6 PUFA intakes. All tests of statistical significance were 2-sided, and the type I error was set at 5%. Statistical analyses were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, North Carolina).
RESULTS

Subject characteristics
Among the 3,749 adults with a CES-D completed in 1996, 2,865 had available dietary data. A total of 121 subjects were excluded because of missing covariate values, leaving a sample of 2,744 subjects for the cross-sectional analyses (Figure 1) .
At baseline, women and men were 47 (standard deviation (SD), 7) and 52 (SD, 5) years of age, respectively (P < 0.001). The energy-adjusted mean intake of n-3 PUFAs was 1.32 g/day (SD, 0.54).
Characteristics of the population across quartiles of n-3 PUFA intake are shown in Table 1 . Subjects were older and more educated across increasing quartiles of total n-3 PUFA intake. In addition, they had lower energy intake from carbohydrates and higher energy intake from lipids and proteins and higher alcohol intake with increasing n-3 PUFA quartiles overall.
Cross-sectional association between PUFA intake and depressive symptoms
The cross-sectional associations are shown in Table 2 . A total of 617 women and 298 men displayed depressive symptoms. In multivariate models, increasing intake of n-3 PUFAs was associated with a lower probability of having depressive symptoms (P for trend ¼ 0.001). This was observed for a-linolenic acid, DPA, EPA, and DHA.
Lower probabilities of having depressive symptoms with increasing n-6 PUFA intake and n-6:n-3 ratio were observed in unadjusted models, but this did not remain significant in the multivariate model. No interactions between supplementation group and PUFA intake (all P's > 0.05), between a-linolenic acid and linoleic acid intakes (P ¼ 0.62), or between n-3 and n-6 PUFA intakes (P ¼ 0.17) regarding depressive symptoms were detected.
Longitudinal association between PUFA intake and depressive symptoms
From the cross-sectional sample, 913 participants were excluded because of missing longitudinal data. Compared with those excluded, participants with longitudinal data were older, more physically active, and more likely to cohabit, were less often current smokers, were more often allocated to the active group during the trial phase, and reported less antidepressant medication use at baseline. They also displayed higher intakes of vitamin C, vitamin E, a-linolenic acid, linoleic acid, EPA, and DHA (data not tabulated).
After excluding prevalent cases (n ¼ 596), we estimated longitudinal associations between PUFA intake and depressive symptoms in a sample of 1,235 participants (Table 3) . A total of 47 men and 93 women were identified as being incident cases of depressive symptoms during a median interval between the two CES-D assessments of 10.8 years.
No interactions between supplementation group or gender and PUFA intake (all P's > 0.05), between a-linolenic acid and linoleic acid intakes (P ¼ 0.66), or between n-3 and n-6 PUFA intakes (P ¼ 0.77) regarding depressive symptoms were detected.
DISCUSSION
In the present study, an inverse association was observed between n-3 PUFA intake and depressive symptoms in midlife, independently of health behaviors or vascular factors. Specifically, higher intakes of total n-3 PUFAs, DHA, DPA, and EPA were associated with lower odds of depressive symptoms in a cross-sectional analysis. As previously reported, PUFA intakes in the SU.VI.MAX population were relatively high, except that of a-linolenic acid, which was below the French recommendations (34) .
The primary strength of this study was the possibility of performing both cross-sectional and longitudinal analyses in the same population. Additionally, an original aspect of our study was the long follow-up period, allowing assessment of the impact of diet at midlife on subsequent depressive symptoms. Further, food consumption was assessed through repeated 24-hour dietary records, strengthening the accuracy of nutrient intake estimates. Our findings, added to the body of evidence from epidemiologic studies, argue for the plausibility of the observed cross-sectional relations.
Some limitations should be acknowledged. First, antidepressant medication use was not reported at the initial CES-D assessment, potentially leading to an artificially decreased presence of depressive symptoms among treated participants. A direct comparison with data on depression prevalence, in light of the fact that many cases of major depression are undiagnosed, was not possible, since we focused on depressive symptoms and self-reported antidepressant medication use. In addition, because the analyses were based on a subsample of the SU.VI.MAX cohort, our findings should be cautiously considered when assessing their external validity. In particular, subjects with CES-D data may have been particularly health-conscious, as shown in other studies (35) , limiting the generalizability of the findings. It is also possible that the statistical power of our study was insufficient to In model 2a, results were adjusted for age (years), gender, physical activity (irregular, equivalent of walking for <1 hour/day, or equivalent of walking for 1 hour/day), educational level (primary, secondary, or university), intervention group (active vs. placebo), energy intake (kcal/day), marital status (cohabiting vs. living alone), number of 24-hour dietary records, alcohol consumption (g/day), body mass index (weight (kg)/height (m) 2 ), saturated fatty acid intake, and vegetable and fruit consumption (g/day).
d In model 2b, results were adjusted for all model 2 factors plus n-6 PUFA intake. e In model 2c, results were adjusted for all model 2 factors plus n-3 PUFA intake.
detect an association between fatty acid intake and incidence of depressive symptoms. Finally, biomarkers of PUFA intake were not available in our study. Self-reported intakes showed some limitations (36) , but differential dietary misclassification according to CES-D score is unlikely after accounting for other factors such as gender, age, and education and after removing prevalent cases.
Most previous epidemiologic studies supported a crosssectional inverse association between n-3 PUFA intake or biologic status and depressive disorders or clinical depression (10, 16, 37) . Findings based on short-term biomarker status, in blood or in the erythrocyte membrane, have provided similar findings (11, 38) . In a recent meta-analysis of casecontrol studies, Lin et al. (11) reported significantly lower concentrations of total n-3 PUFAs, and to a lesser extent lower concentrations of EPA and DHA, among depressed subjects compared with controls. All of these results are in concordance with our cross-sectional findings. However, cross-sectional designs do not allow making inferences about the temporal ordering of n-3 PUFA intake and depression or depressive symptoms.
To the best of our knowledge, only 1 published randomized clinical trial has been designed with a primary prevention objective (19) regarding the link between n-3 PUFAs and depression. This randomized clinical trial, initiated among nondepressed Dutch subjects, showed no effect of combined EPA and DHA supplementation (400 mg/day or 1,800 mg/day) on depressive symptoms assessed after a 13-or 26-week intervention period (19) . That study did not support an effect of nutritional doses (400 mg/day corresponds approximately to consumption of fish 2 times per week) on depressive symptoms among healthy subjects.
Some longitudinal observational studies, although relatively scarce, have focused on the impact of n-3 PUFAs on the incidence of depression in healthy populations (20, 39) . Despite heterogeneous study designs, population samples, outcome measures, and methods used for dietary assessment, these authors have reported null results regarding high levels of n-3 PUFA intake and prevention of depression. In contrast, Colangelo et al. (40) reported a significant association between high n-3 PUFA intakes and lower odds of depressive symptoms; however, the CES-D was used approximately 13 years after diet assessment, without taking baseline CES-D values into consideration. Thus, it is also likely that a cross-sectional association between baseline depressive symptoms and PUFA existed. In that case, the long-term association might reflect only the cross-sectional patterns.
The lack of evidence from the randomized clinical trial noted above (19) adds to the absence of significant findings from other longitudinal studies (20) and supports the hypothesis of no effect of high n-3 PUFA intakes on depression in a primary prevention context. These observations raise the possibility of reverse causality as regards the association between depression and n-3 PUFAs in cross-sectional designs. In other words, rather than the nutrients' affecting depression, we could speculate that persons exhibiting elevated levels of depressive symptoms might have decreased n-3 PUFA intakes, possibly due to a disrupted appetite and/or decreased engagement in health-promoting behaviors. This is of major interest from a public health viewpoint, since a poor n-3 PUFA status has been associated with several other health outcomes (41) .
In conclusion, our study helps clarify the conflicting findings in the literature regarding the relation between n-3 PUFA intake and depressive symptoms. In particular, our results stress the fact that cross-sectional or longitudinal studies without data on depression or depressive symptoms at baseline are liable to obscure important associations and are not positioned to test temporality regarding the relation between diet and outcome. Our results do not support an association between n-3 PUFA intake and risk of depressive symptoms. Rather, they suggest that reduced n-3 PUFA intake might be part of the profile of subjects with depressive symptoms, many of whom are elderly.
